Angiogenesis inhibitor and Kaposi sarcoma.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017321:Clinical Trials, Phase I as Topic; D004305:Dose-Response Relationship, Drug; D015658:HIV Infections / Q000150:complications*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D010787:Photosensitivity Disorders / Q000139:chemically induced; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000821:virology*; D013752:Tetracycline / Q000009:adverse effects*; D013754:Tetracyclines
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013754:Tetracyclines; C117155:tetracycline CMT-3; D013752:Tetracycline